Germany - Re-Imbursed Pharmaceutical Market
Since 2014, Germany Re-Imbursed Pharmaceutical Market decreased by 1.9points year on year. At 32.9 Percent of Generics in Value in 2019, the country was ranked number 5 comparing other countries in Re-Imbursed Pharmaceutical Market. Germany is overtaken by New Zealand, which was ranked number 4 with 33.1 Percent of Generics in Value and is followed by Canada with 26.8 Percent of Generics in Value. Austria lead the ranking with 52.2 Percent of Generics in Value in 2019, that is a growth of 2.8points compared to 2018. Denmark recorded the best 5 years average growth at +6.9points per year, while Slovakia witnessed the worst performance at -7.8points per year.
Loading...
| Date | Percent of Generics in Value |
|---|---|
| 2019 | 32.90 |
| 2018 | 32.40 |
| 2017 | 34.60 |
| 2016 | 34.10 |
| 2015 | 35.60 |
Download all data from 2000 to 2019
How does Germany rank in Re-Imbursed Pharmaceutical Market?
| # | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
| 2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
| 4 |
#4
New Zealand
|
33.10 % | 2019 | +1.2 % | +0.7 % | View data | |
| 5 |
#5
Germany
|
32.90 % | 2019 | +1.5 % | -1.9 % | View data | |
| 6 |
#6
Canada
|
26.80 % | 2019 | -2.9 % | -4.1 % | View data | |